IQVIA Belux reposted this
CAR T-cell therapies can be life-changing. Access remains far from equal. Since their first approval in 2017, CAR T-cell therapies have transformed treatment options for patients with advanced hematological malignancies. Yet nearly a decade later, many eligible patients still do not receive these therapies. Why? The challenge is often health system readiness. Our latest IQVIA Institute report examines how governments can help remove barriers to access by strengthening: • Governance and strategic planning • Financing and reimbursement models • Facility readiness and capacity • Workforce expertise • Referral pathways • Outcomes monitoring and data infrastructure Drawing on lessons from France, Germany, Spain, Italy, the UK, Australia, and Canada, the report identifies best practices and policy recommendations to support equitable access to CAR T-cell therapies at scale. Download the report: https://bit.ly/4yJEBiB